{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:42:08Z","timestamp":1790484128839,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents","doi-asserted-by":"crossref","award":["2010-190-4"],"award-info":[{"award-number":["2010-190-4"]}],"id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Pharmacy of Zhejiang Medical Key Discipline","award":["2018-2-3"],"award-info":[{"award-number":["2018-2-3"]}]},{"name":"Clinical Pharmacy of Hangzhou Medical Key Discipline","award":["2017-68-7"],"award-info":[{"award-number":["2017-68-7"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3418-9","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:58:23Z","timestamp":1539205103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Changcheng","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"3418_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","volume":"19","author":"KB Laupland","year":"2013","unstructured":"Laupland KB, Lyytik\u00e4inen O, S\u00f8gaard M, Kennedy KJ, Knudsen JD, Ostergaard C, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect. 2013;19:465\u201371.","journal-title":"Clin Microbiol Infect"},{"key":"3418_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/345476","volume":"36","author":"SE Cosgrove","year":"2003","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53\u20139.","journal-title":"Clin Infect Dis"},{"key":"3418_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","volume":"61","author":"JS McDanel","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61:361\u20137.","journal-title":"Clin Infect Dis"},{"key":"3418_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","volume":"15","author":"D Wong","year":"2016","unstructured":"Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016;15:27.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"3418_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the american heart association. Circulation. 2015;132:1435\u201386.","journal-title":"Circulation"},{"issue":"625","key":"3418_CR6","first-page":"e1","volume":"33","author":"F Gudiol","year":"2015","unstructured":"Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Dom\u00ednguez M\u00c1, et al. Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015;33(625):e1\u2013e23.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"3","key":"3418_CR7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"Catherine Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u201355.","journal-title":"Clinical Infectious Diseases"},{"key":"3418_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1\u201345.","journal-title":"Clin Infect Dis"},{"key":"3418_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.1892","volume":"37","author":"J Li","year":"2017","unstructured":"Li J, Echevarria KL, Traugott KA. \u03b2-Lactam therapy for methicillin-susceptible Staphylococcus aureus bacteremia: a comparative review of cefazolin versus antistaphylococcal penicillins. Pharmacotherapy. 2017;37:346\u201360.","journal-title":"Pharmacotherapy"},{"key":"3418_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cmi.2017.07.003","volume":"24","author":"P Loubet","year":"2018","unstructured":"Loubet P, Burdet C, Vindrios W, Grall N, Wolff M, Yazdanpanah Y, et al. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect. 2018;24:125\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"3418_CR11","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration. 2011. \n                    https:\/\/handbook-5-1.cochrane.org\n                    \n                  ."},{"key":"3418_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"3418_CR13","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1128\/AAC.00485-11","volume":"55","author":"S Lee","year":"2011","unstructured":"Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother. 2011;55:5122\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","volume":"17","author":"M Paul","year":"2011","unstructured":"Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011;17:1581\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"3418_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1542-4758.2010.00507.x","volume":"15","author":"CJ Renaud","year":"2011","unstructured":"Renaud CJ, Lin X, Subramanian S, Fisher DA. High-dose cefazolin on consecutive hemodialysis in anuric patients with staphylococcal bacteremia. Hemodial Int. 2011;15:63\u20138.","journal-title":"Hemodial Int"},{"key":"3418_CR16","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1128\/AAC.02800-14","volume":"58","author":"J Li","year":"2014","unstructured":"Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58:5117\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dku560","volume":"70","author":"AD Bai","year":"2015","unstructured":"Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother. 2015;70:1539\u201346.","journal-title":"J Antimicrob Chemother"},{"key":"3418_CR18","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1128\/AAC.04677-14","volume":"59","author":"SN Rao","year":"2015","unstructured":"Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J, et al. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015;59:5232\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR19","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1128\/AAC.00243-16","volume":"60","author":"S Pollett","year":"2016","unstructured":"Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. Cefazolin versus Nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a California tertiary medical center. Antimicrob Agents Chemother. 2016;60:4684\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","volume":"6","author":"LK Flynt","year":"2017","unstructured":"Flynt LK, Kenney RM, Zervos MJ, Davis SL. The safety and economic impact of cefazolin versus Nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Infect Dis Ther. 2017;6:225\u201331.","journal-title":"Infect Dis Ther"},{"key":"3418_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cix287","volume":"65","author":"JS McDanel","year":"2017","unstructured":"McDanel JS, Roghmann MC, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis. 2017;65:100\u20136.","journal-title":"Clin Infect Dis"},{"key":"3418_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","volume":"24","author":"S Lee","year":"2018","unstructured":"Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect. 2018;24:152\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"3418_CR23","doi-asserted-by":"publisher","first-page":"e01816","DOI":"10.1128\/AAC.01816-17","volume":"62","author":"Khalid Eljaaly","year":"2018","unstructured":"Eljaaly K, Alshehri S, Erstad BL. Systematic review and meta-analysis of the safety of Antistaphylococcal Penicillins compared to cefazolin. Antimicrob Agents Chemother. 2018. \n                    https:\/\/doi.org\/10.1128\/AAC.01816-17\n                    \n                  .","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"3418_CR24","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1128\/AAC.40.12.2686","volume":"40","author":"F Soriano","year":"1996","unstructured":"Soriano F, Garc\u00eda-Corbeira P, Ponte C, Fern\u00e1ndez-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother. 1996;40:2686\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR25","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.1128\/AAC.01517-16","volume":"60","author":"SH Lee","year":"2016","unstructured":"Lee SH, Park WB, Lee S, Park S, Kim SW, Lee JM, et al. Association between type a blaZ gene polymorphism and cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2016;60:6928\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR26","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1128\/AAC.00317-09","volume":"53","author":"EC Nannini","year":"2009","unstructured":"Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother. 2009;53:3437\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"3418_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","volume":"34","author":"YP Chong","year":"2015","unstructured":"Chong YP, Park SJ, Kim ES, Bang KM, Kim MN, Kim SH, et al. Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome. Eur J Clin Microbiol Infect Dis. 2015;34:349\u201355.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3418_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1089\/mdr.2013.0229","volume":"20","author":"S Lee","year":"2014","unstructured":"Lee S, Kwon KT, Kim HI, Chang HH, Lee JM, Choe PG, et al. Clinical implications of cefazolin inoculum effect and \u03b2-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Microb Drug Resist. 2014;20:568\u201374.","journal-title":"Microb Drug Resist"},{"issue":"10","key":"3418_CR29","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/jac\/dky259","volume":"73","author":"Monique R Bidell","year":"2018","unstructured":"Bidell MR, Patel N, O'Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018. \n                    https:\/\/doi.org\/10.1093\/jac\/dky259\n                    \n                  .","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"3418_CR30","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/bcp.13554","volume":"84","author":"JP Rindone","year":"2018","unstructured":"Rindone JP, Mellen CK. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia. Br J Clin Pharmacol. 2018;84:1258\u201366.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3418-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3418-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3418-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:06:50Z","timestamp":1570734410000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3418-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3418-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"508"}}